{"id":10311,"date":"2026-09-15T07:16:40","date_gmt":"2026-09-15T12:16:40","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10311"},"modified":"2026-09-15T07:25:05","modified_gmt":"2026-09-15T12:25:05","slug":"nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","title":{"rendered":"Nanoscope Therapeutics presentar\u00e1 datos a largo plazo sobre MCO-010 en la 59.\u00aa Reuni\u00f3n Anual de la Sociedad de Retina."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10311\" class=\"elementor elementor-10311\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul type=\"disc\"><li><i>La Dra. Christine Kay presentar\u00e1 datos de seguimiento a largo plazo de 4 a\u00f1os del ensayo RESTORE de fase 2b\/3 en pacientes con retinosis pigmentaria.<\/i><\/li><\/ul><p><span class=\"legendSpanClass\">DALLAS<\/span>,\u00a0<span class=\"legendSpanClass\">15 de septiembre de 2026<\/span>\u00a0\u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Terap\u00e9utica del nanoscopio<\/a>, Inc., una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que la Dra. Christine Kay, Directora de Investigaci\u00f3n Cl\u00ednica y Gen\u00e9tica Retiniana de Vitreoretinal Associates en Gainesville, presentar\u00e1 datos de 4 a\u00f1os del programa MCO-010 de Nanoscope para la retinosis pigmentaria en el\u00a0<a href=\"https:\/\/www.retinasociety.org\/page\/2\/annual-meeting\" target=\"_blank\" rel=\"nofollow noopener\"><b>59<\/b><b><sup>th<\/sup><\/b><b>\u00a0Reuni\u00f3n Cient\u00edfica Anual de la Sociedad de Retina<\/b><\/a><b>, que tendr\u00e1 lugar del 23 al 26 de septiembre de 2026 en Los \u00c1ngeles, California.<\/b><\/p><p><b>Detalles de la presentaci\u00f3n:<\/b><\/p><p><b>T\u00edtulo de presentaci\u00f3n:\u00a0<\/b><i>Mejora duradera de la visi\u00f3n con la terapia optogen\u00e9tica MCO-010: datos del estudio REMAIN de 4 a\u00f1os del ensayo RESTORE de fase 2b\/3 para la retinosis pigmentaria.<br \/><\/i><b>Presentador:\u00a0<\/b>Christine Kay, doctora en medicina<br \/><b>Fecha y hora:\u00a0<\/b>Mi\u00e9rcoles, 23 de septiembre de 2026, 15:15 (hora del Pac\u00edfico)<br \/><b>Ubicaci\u00f3n:\u00a0<\/b>Hotel Fairmont Century Plaza, Los \u00c1ngeles, California<\/p><p>El Dr. Kay presentar\u00e1 datos ampliados sobre la durabilidad a largo plazo del beneficio para el paciente en pacientes tratados con MCO-010 (sonpiretigene isteparvovec, MOGENRY\u00ae). Estos datos demuestran que los pacientes tratados con MOGENRY\u00ae contin\u00faan manteniendo las mejoras en la agudeza visual mucho despu\u00e9s del tratamiento. MOGENRY\u00ae es el \u00fanico programa que demuestra una restauraci\u00f3n sostenida de la agudeza visual con durabilidad a largo plazo, y la BLA para MOGENRY\u00ae<a href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">\u00a0Ha sido aceptado y archivado por la FDA.<\/a>.<\/p><p><b>Acerca de MOGENRY\u00ae (sonpiretigene isteparvovec; MCO-010)<\/b><\/p><p>La tecnolog\u00eda de opsina multicaracter\u00edstica (MCO) de Nanoscope utiliza una opsina sint\u00e9tica patentada, modificada gen\u00e9ticamente, para optimizar su rendimiento en t\u00e9rminos de alta sensibilidad a la luz en un amplio espectro y una cin\u00e9tica r\u00e1pida. Tras la concepci\u00f3n e invenci\u00f3n de la tecnolog\u00eda por parte de Samarendra Mohanty, cofundador, presidente y director cient\u00edfico de Nanoscope, su equipo ha dedicado m\u00e1s de una d\u00e9cada a evaluar su rendimiento en diversos modelos animales y enfermedades humanas. MOGENRY\u00ae es una terapia g\u00e9nica optogen\u00e9tica intrav\u00edtrea experimental, de una sola aplicaci\u00f3n y administrada en consulta, basada en la plataforma MCO de Nanoscope. Al administrar un gen de opsina multicaracter\u00edstica a las c\u00e9lulas bipolares de la retina, de alta densidad, MOGENRY\u00ae confiere a estas c\u00e9lulas supervivientes sensibilidad directa a la luz, permiti\u00e9ndoles utilizar el circuito visual restante tras la p\u00e9rdida de fotorreceptores. MOGENRY\u00ae no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, y est\u00e1 dise\u00f1ado para su administraci\u00f3n dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><b>Acerca de Nanoscope Therapeutics<\/b><\/p><p>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4773022-1&amp;h=610580003&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04945772___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoyYzIwMjMwOGRmZmU0NDVlNzU1NDhhOTVlMDAzZTM1MTo3OmEyNmQ6NWRkNDk4NDJiOTMyYmNlYjczNDA1M2E3NDI0ODNiZTgwY2VhNmVmOWUyOGJjMjg3NzI3NzMzNTg4YmY2YWYzYjpwOlQ6Rg&amp;a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), el\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">La FDA ha aceptado y presentado la solicitud de licencia biol\u00f3gica (BLA) de la compa\u00f1\u00eda para MOGENRY\u00ae.<\/a>. Si se aprueba, MOGENRY\u00ae tiene el potencial de convertirse en el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar un ensayo de registro de Fase 3 en 2026. MCO-010 ha recibido las designaciones de V\u00eda R\u00e1pida y Medicamento Hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de Medicamento Hu\u00e9rfano de la EMA que cubren distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. MCO-010 tambi\u00e9n ha recibido las designaciones de Sakigake y Medicamento Hu\u00e9rfano para distrofias retinianas hereditarias (IRD) en Jap\u00f3n y una designaci\u00f3n de Medicamento Hu\u00e9rfano para IRD en Arabia Saudita. Se espera que un programa de Fase 2 para MCO en atrofia geogr\u00e1fica comience en 2026, y otros programas listos para IND incluyen amaurosis cong\u00e9nita de Leber (LCA).<\/p><p><b>Contacto:<\/b><\/p><p>Nanoscope Therapeutics, Inc.<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><u><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/u><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p><p><img decoding=\"async\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DA46696&amp;Transmission_Id=202609150702PR_NEWS_USPR_____DA46696&amp;DateId=20260915\" alt=\"\" \/><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Christine Kay, MD, to present 4-year long-term follow-up data from the RESTORE Phase 2b\/3 trial in retinitis pigmentosa patients DALLAS,\u00a0Sept. 15, 2026\u00a0&#8212;\u00a0Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Dr. Christine Kay, Director of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10313,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10311","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-15T12:16:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-15T12:25:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting\",\"datePublished\":\"2026-09-15T12:16:40+00:00\",\"dateModified\":\"2026-09-15T12:25:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\"},\"wordCount\":550,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MIDDLE_2025.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MIDDLE_2025.jpg\",\"datePublished\":\"2026-09-15T12:16:40+00:00\",\"dateModified\":\"2026-09-15T12:25:05+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MIDDLE_2025.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MIDDLE_2025.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-09-15T12:16:40+00:00","article_modified_time":"2026-09-15T12:25:05+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting","datePublished":"2026-09-15T12:16:40+00:00","dateModified":"2026-09-15T12:25:05+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/"},"wordCount":550,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MIDDLE_2025.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","name":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MIDDLE_2025.jpg","datePublished":"2026-09-15T12:16:40+00:00","dateModified":"2026-09-15T12:25:05+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MIDDLE_2025.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MIDDLE_2025.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10311"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10311\/revisions"}],"predecessor-version":[{"id":10319,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10311\/revisions\/10319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10313"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}